An Expert’s Guide to WCLC 2022: A Preview of the Top Abstracts

During the IASLC 2022 WCLC Annual Meeting, important results from many clinical trials in lung cancer and thoracic oncology will be reported. Lung cancer experts, Heather Wakelee, MD, and Wade T. Iams, MD, MSCI, have highlighted their most anticipated abstracts, which we will cover online as a part of CCO’s Independent Conference Coverage of WCLC 2022. Remember to check the CCO website often as the meeting unfolds for downloadable slidesets summarizing the data from these studies and then again for a CME-certified online text module featuring expert analyses and perspectives on the clinical implications of the new data.

Heather Wakelee, MD, and Wade T. Iams, MD, MSCI, identified several key studies in lung cancer of interest at WCLC 2022, including those being presented in the plenary session.

• The Yorkshire Enhanced Stop Smoking Study (YESS) (abstract PL03.03): Authors will present data from personalized smoking cessation support services as part of a lung cancer screening program, the Yorkshire Lung Screening Trial (YLST).
• The international randomized phase III CALGB 140503 (Alliance) trial (abstract PL03.06): Results from this trial of lobar vs sublobar resection for peripheral clinical stage IA non-small-cell lung cancer (NSCLC) are highly anticipated by surgeons.
• The phase III IMpower010 trial with atezolizumab vs best supportive care in resected NSCLC (abstract PL03.09): Overall survival (OS) results for all recently approved regimens in resectable NSCLC are highly awaited. The FDA approval of adjuvant atezolizumab was based on disease-free survival benefit, so the potential for showing an improved cure rate with adjuvant atezolizumab vs supportive care is still a major unmet need, making these data highly anticipated.
• Progression-free survival (PFS) and OS results from the phase II NADIM II study of neoadjuvant nivolumab plus chemotherapy vs chemotherapy alone in patients with resectable stage IIIA/B NSCLC (abstract PL03.12): Similar to the Impower010 trial, the FDA approval of neoadjuvant nivolumab plus platinum-doublet chemotherapy was based on event-free survival benefit and pathologic complete response rates, so ultimately proving improved cure rate with neoadjuvant nivolumab plus chemotherapy is still an unmet need, and these data are highly anticipated.
• The phase I/II CodeBreaK 100/101 studies of sotorasib in combination with pembrolizumab or atezolizumab for patients with advanced NSCLC and KRAS G12C mutations (abstract OA03.06): Results of CodeBreaK 101 will be presented as well as updated results from CodeBreaK 100, with the potential to move sotorasib to the first-line setting.

Additional studies to watch include:

• The phase II HUDSON umbrella trial with biomarker-directed treatment for patients who have progressed on an anti–PD-1 or anti–PD-L1 therapy (abstract OA15.05).
• A pooled analysis from 5 phase III studies of patients who received a second course of pembrolizumab monotherapy following progression after either completing 35 cycles of pembrolizumab (with or without chemotherapy) with stable disease or better or stopping pembrolizumab before 35 cycles due to complete response (abstract OA15.06).
• Phase I TROPION-Lung02 study with datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy for patients with advanced NSCLC (abstract MA13.07).
• Phase I data for the DLL3-targeted T-cell engager tarlatamab for patients with small-cell lung cancer (abstract OA12.05).
• Results of CodeBreaK 101 master study with sotorasib plus RMC-4630, an SHP2 inhibitor, in patients with solid tumors expressing KRAS G12C mutations. (abstract OA03.03)
• A population-based study in the United Kingdom assessing socio-economic treatment inequalities with biomarker-guided targeted therapy and immunotherapy for patients with NSCLC. (abstract OA01.05)